Business Context and Reporting Period
ADC Therapeutics SA, a Swiss foreign private issuer, filed this Form 6-K for August 2020 on August 14, 2020. The filing reports a change in senior management and does not provide financial statements or operating results.
Financial and Operating Metrics
The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Dominique Graz notified the company that he will resign as General Counsel and Secretary effective September 30, 2020 to pursue a new opportunity.
- Michael Forer, Vice Chairman and Executive Vice President, will assume the General Counsel role effective October 1, 2020, while retaining his current positions.
Guidance, Risks, and Unusual Items
The filing provides no guidance, outlook, management commentary on financial performance, contingencies, or specific risks. The disclosed legal and management transition could be relevant to governance and continuity but is not quantified in the filing.
Investor Verification Points
- Confirm the completion of Mr. Graz’s departure on September 30, 2020.
- Confirm Mr. Forer’s appointment as General Counsel effective October 1, 2020 and his continued responsibilities as Vice Chairman and Executive Vice President.
- Review subsequent filings for any further changes in executive responsibilities or governance.